Genomic and Biologic Therapies for ADRD
Funds moving a genomic or biologic therapy candidate for Alzheimer's-related dementias from lab optimisation through to first human testing.
Gene and biologic therapies are opening new ways to treat, prevent or even change the course of Alzheimer's disease-related dementias, but getting one from the lab to a patient is still blocked by delivery, safety, manufacturability and readiness-for-clinic problems. This notice funds clearing those blocks for candidates that already have solid preclinical evidence behind them.
What is funded run…
Optimisation and translational development of genomic and biologic therapeutic candidates, with compelling preclinical evidence, for Alzheimer's disease-related dementias — spanning design and manufacturability refinement, pharmacology and toxicology, IND-enabling data generation, and first-in-human evaluation, prioritising frontotemporal degeneration, Lewy body dementia and vascular contributions to cognitive impairment and dementia.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up